In:
Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 97, No. 48 ( 2018-11), p. e13464-
Abstract:
Advanced non-small-cell lung cancer (NSCLC) is an aggressive malignancy that generally leads to poor outcomes, with 〈 5% long-term survival at 5 years; however, several researches have shown improvements in the progression-free survival (PFS) and overall survival (OS) on the maintenance therapy after the first-line chemotherapy. we report a case of metastatic NSCLC patient treated with maintenance therapy of gemcitabine with brilliant results. Patient concerns: Clinical data and treatment of a 68-year-old man with NSCLC are summarized. The Ethics Committee of People's hospital of Leshan, approved this study. Diagnosis: Lung adenocarcinoma metastasized to the mediastinal lymph node, cervical lymph node, and adrenal gland, without epidermal growth factor receptor (EGFR) mutation. Interventions: Continued treatment with gemcitabine alone following the 6 cycles of cisplatin–gemcitabine chemotherapy, prolonging the interval of chemotherapy when he could not tolerate the toxicity of the drug. Outcomes: Partial response of the disease for 4.5 years and significant clinical benefit. Lessons: This case shows that patients will benefit from the maintenance therapy, and gemcitabine may be a good choice.
Type of Medium:
Online Resource
ISSN:
0025-7974
,
1536-5964
DOI:
10.1097/MD.0000000000013464
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2018
detail.hit.zdb_id:
2049818-4
Bookmarklink